CS MEDICA receives 2 MDKK to support its short-term financial obligations.

CS MEDICA A/S (“CS MEDICA” or “the Company”) announces it has received a loan of 2 million DKK to support its short and mid-term funding requirements. This financial support is facilitated through an agreement involving LHX Invest ApS (“LHX Invest”), owned by Lone Henriksen, CEO of CS MEDICA, ProArk Ejendomsinvest (“ProArk”), and CS MEDICA.

LHX Invest has concluded an agreement with ProArk, securing funding of 2 MDKK to CS MEDICA. The Agreement is based on the following terms;

  • As collateral for the funding, LHX Invest, owned by Lone Henriksen, CEO of CS MEDICA has transferred 1,333,333 common shares of CS MEDICA to ProArk.
  • CS MEDICA must within 8 months, pay ProArk 4 MDKK, (giving an effective interest rate of 100%) to get the shares back, ensuring the shares in full are returned to LHX Invest. If payments are not secured the shares will fall to ProArk.

Gitte Lund Henriksen, CFO of CS MEDICA, stated, “While this is an expensive solution, it reinforces our commitment to achieving our strategic objectives and allows us to avoid dilution of our shares. This injection of 2 million DKK is crucial for supporting our immediate financial needs.”

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect current expectations and projections about future events and are based on currently available information. Actual results may differ materially from those anticipated in such statements due to various factors.